The First Affiliated Hospital with Nanjing Medical University: Carcinoma, Hepatocellular trials
The registry lists 10 Carcinoma, Hepatocellular studies with The First Affiliated Hospital with Nanjing Medical University as lead sponsor. 5 are open to participants now and 0 have results posted.
Phase 2 5Phase 3 1Phase 4 1No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular CarcinomaNot yet recruitingNCT07131501Phase 2
- Clinical Study on the Effectiveness and Safety of Lenvatinib As Adjuvant Treatment for Patients with High-risk Recurrence of Hepatocellular Carcinoma After SurgeryRecruitingNCT06762782Phase 2
- Immunotherapy for Hepatocellular CarcinomaRecruitingNCT06241326
- Goal-directed LCVP Based on HP in Laparoscopic HepatectomyRecruitingNCT05887661Not applicable
- Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular CarcinomaRecruitingNCT05613478Phase 3
- The Effects of Oxycodone Versus Sufentanil on Pain and Inflammatory Response After TACECompletedNCT06041425Phase 4
- Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver TransplantationStatus unknownNCT05355155Phase 2
- SHR-1210 Combined With Apatinib Mesylate in the Perioperative Treatment of Hepatocellular CarcinomaStatus unknownNCT04297202Phase 2
- Anlotinib Hydrochloride Combined With Sintilimab Injection in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04052152Phase 2
- Anlotinib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT03766776Not applicable